Intellectual Property Rights and Health Rights: A Feasible Reform Proposal to Facilitate Access to Drugs in Developing Countries

Authors: M. G. Cattaneo

Abstract:

The non-effectiveness of certain codified human rights is particularly apparent with reference to the lack of access to essential drugs in developing countries, which represents a breach of the human right to receive adequate health assistance. This paper underlines the conflict and the legal contradictions between human rights, namely health rights, international Intellectual Property Rights, in particular patent law, as well as international trade law. The paper discusses the crucial links between R&D costs for innovation, patents and new medical drugs, with the goal of reformulating the hierarchies of priorities and of interests at stake in the international intellectual property (IP) law system. Different from what happens today, International patent law should be a legal instrument apt at rebalancing an axiological asymmetry between the (conflicting) needs at stake The core argument in the paper is the proposal of an alternative pathway, namely a feasible proposal for a patent law reform. IP laws tend to balance the benefits deriving from innovation with the costs of the provided monopoly, but since developing countries and industrialized countries are in completely different political and economic situations, it is necessary to (re)modulate such exchange according to the different needs. Based on this critical analysis, the paper puts forward a proposal, called Trading Time for Space (TTS), whereby a longer time for patent exclusive life in western countries (Time) is offered to the patent holder company, in exchange for the latter selling the medical drug at cost price in developing countries (Space). Accordingly, pharmaceutical companies should sell drugs in developing countries at the cost price, or alternatively grant a free license for the sale in such countries, without any royalties or fees. However, such social service shall be duly compensated. Therefore, the consideration for such a service shall be an extension of the temporal duration of the patent’s exclusive in the country of origin that will compensate the reduced profits caused by the supply at the price cost in developing countries.

Keywords: Global health, global justice, patent law reform, access to drugs.

Digital Object Identifier (DOI): doi.org/10.5281/zenodo.1131729

References:

[1] The Universal Declaration of Human Rights, (December 10, 1948), U.N. Doc. A/RES/217 (III), Articles 25.
[2] Tobin J., The Right To Health in International Law, Oxford, 2012, pp. 75 and ff.
[3] Helfer L. R., Austin G. W., Human Rights and Intellectual Property Mapping the Global Interface, Cambridge 2011.
[4] Contaldi G., La tutela delle invenzioni nel sistema OMC, esclusiva brevettuale e valori emergenti nella comunità internazionale, Milano 2009.
[5] Cassese A., Gaeta P., Le sfide attuali del diritto internazionale, Bologna 2008, pp. 275-278.
[6] T. Pogge, Povertà mondiale e diritti umani, edited by L. Caranti, translated by D. Botti, Roma-Bari 2010.
[7] TRIPS Agreement (Agreement on Trade- Related Aspects of Intellectual Property Rights).
[8] P. K. Yu, Intellectual Property and Human Rights in the Nonmultilateral Era, in Florida Law Review, vol. 64, July 2012.
[9] M. Angell M. D., The truth about the Drug companies, New York 2004, pp. 52-57.
[10] The Universal Declaration of Human Rights, (December 10, 1948), U.N. Doc. A/RES/217 (III), Articles 25 (1) and 27 (1).
[11] International Covenant on Economic, Social and Cultural Rights (ICESCR) (December 16, 1966), U.N. Doc. A/RES/21/2200 Article 15 1 (c).
[12] Landes W. M., Posner R. A., The economic structure of intellectual property law, Cambridge Massachussetts 2003.
[13] Sena G., I diritti sulle invenzioni e sui modelli industriali, in Trattato di diritto civile e commerciale, Cicu A. and Messineo F., Milano 1984, pp. 28 and ff.
[14] Vanzetti A. e Di Cataldo V., Manuale di diritto industriale, Milano 2005.
[15] Casaburi G., Concorrenza sleale e diritti di proprietà industriale, in Il Diritto Industriale, 5/2012, pp. 397 and ff.
[16] Floridia G., Principi attivi e specialità farmaceutiche nella disciplina dei brevetti, in Il Diritto Industriale, 6/2004, pp. 513 and ff..
[17] Galli C., Per un approccio realistico al diritto dei brevetti, in Il Diritto Industriale, 2/2010, pp. 133 and ff.
[18] In this sense also Franzosi M., Il concetto di equivalenza in Il Diritto Industriale, 3/2005, pp. 253 and ff..
[19] Musso A. Ditta e insegna. Marchio. Brevetti. Disegni e modelli. Concorrenza, in Commentario del codice civile e codici collegati Scialoja-Branca-Galgano, edited by De Nova G., Bologna 2012, pp. 533 and ff. and, in particular, pp. 541-548.
[20] Acconci P., Tutela della salute e diritto internazionale, Padova 2011, p. 5 and 14.
[21] Wolff J., The Human Right to Health, New York 2012.
[22] Pogge T., The Health Impact Fund and Its Justification by Appeal to Human Rights, in Journal of Social Philosophy, 40, no.4 (2009).
[23] U.N. Economic and Social Council, Committee on Economic, Social and Cultural Rights, General Comment No. 17 (2005) (article 15, paragraph 1 (c), of the Covenant) U.N. Doc. E/C.12/ GC/17 (12 January 2006), 7.
[24] W. Nordhaus, Schumpeterian profits in the American economy: theory and measurement, in National Buro of Economic Research (NBER) working paper series n. 10433\2004.
[25] T. Pogge, Are We Violating the Human Rights of the World's Poor?, Yale Human Rights and Development Journal, vol. 14: Iss. 2, Article 1, 2011.
[26] Vadi V., Balancing the human right to health and intellectual property rights after Doha, in The Italian Yearbook of International Law, edited by Conforti B., Ferrari Bravo L., Francioni F., Ronzitti R., Sacerdoti G., Pavoni R. (assistant editor) vol. 14, Leiden, 2004, 196,197.
[27] General Comment No. 14 paragraphs 33-36, 39.
[28] Hamilton W. H., Property - According to Locke, in Yale L. J., 1932, pp. 867 and ff.
[29] Sonderholm J., Ethical issues surrounding intellectual property rights, in New Frontiers in the Philosophy of Intellectual Property, edited by Lever A., Cambridge 2012, pp. 116 and 117.
[30] Attas D., Lockean Justifications of Intellectual Property, in Intellectual Property and Theories of Justice, edited by Gosseries A., Marciano A., Strowel A., London 2008, pp. 29 and ff.
[31] Rolli R., La proprietà come diritto dell’uomo?, in Contratto e Impresa, 4-5 2011, pp. 1014 and ff.
[32] S. Sandri, La nuova disciplina della proprietà industrial dopo I GATT e TRIPS, Padova 1996.
[33] D. O’Connor, TRIPs: Licensing Challenge, in Les Nouvelles, n.1 vol. 30, 1995, pp. 16-18.
[34] Falce V., Lineamenti giuridici e profili economici della tutela dell’innovazione industriale, Milano 2006, pp. 34 and ff.
[35] Correa C., Implementing the TRIPs Agreement in the Patents Field: Options for Developing Countries, in The Journal of World Intellectual Property, 1, no. 1, 1998.
[36] P. Cullet, Human Rights and Intellectual Property Protection in the TRIPS Era, in Human Rights Quarterly, 29 (2007). .
[37] E. Bonadio, Sistema brevettuale TRIPS e risorse genetiche, Napoli 2008.
[38] C. A. P. Braga, Trade Related Intellectual Property Issues: The Uruguay Round Agreement and Its Economic Implications, in World Bank Discussion Paper, no. 307, 1995;
[39] R. M. Sherwood, The TRIPs Agreement: Implications for Developing Countries, in Industrial Property, JLT, 37, n. 3, pp. 491-544.
[40] M. C. E. J. Bronckers, The Impact of the TRIPs: Intellectual Property Protection in developing Countries, in CMLR, 31, no. 6, 1994, pp. 1273 and ff.
[41] G. Fish, B. Speyer, TRIPs as an Adjustment Mechanism in North- South Trade, in Intereconomics, Review of International Trade and Development, Mach-April 1995, pp. 65 and ff.
[42] E. B. Ituku, Propriété intellectuelle et droits de l’homme, Bruxelles 2007.
[43] T. Cottier, The WTO System and Exhaustion of Rights, Draft, Committee on International Trade Law Conference on the Exhaustion of Intellectual Property Rights and Parallel Importation in World Trade, Genève, 1998, in F. M. Abbott, T. Cottier, F. Gurry, The International Intellectual Property System, Commentary and materials, part two, London/Boston 1999, pp. 1796 and ff..
[44] Srinivas K.R., Open Source drug discovery a revolutionary paradigm or a Utopian model?, in Incentives for Global Public Health, edited by Pogge T., Rimmer M., Rubenstein K., Cambridge 2010, p. 266-268.
[45] Abbott F., The TRIPS Agreement, Access to Medicines and the WTO DOHA Ministerial Conference, 2001, p. 41, on the website: www.quno.org/geneva/pdf/economic/Occasional/Access-to-Medicine7.pdf (June 30, 2010).
[46] Trujillo I., Le nuove frontiere dell’uguaglianza , Bologna.
[47] Cassese A., I Diritti Umani Oggi, Roma - Bari, 2005, p. 60.
[48] Steiner H. J., Alston P., International Human Rights in Context, Oxford 2000, pp. 366-368.
[49] Facchi A., Breve storia dei diritti umani, Bologna 2007, pp. 146-149.
[50] N. Bobbio, L’età dei diritti, Torino 1992, p. 18.
[51] George R. P., Il diritto naturale nell’età del pluralismo, Torino 2011, pp. 203-205.
[52] Zolo D., Chi dice umanità. Guerra diritto e ordine globale, Torino 2000, pp. 42 and ff.
[53] Ignatieff M., Una ragionevole apologia dei diritti umani, Milano 2003, pp. 91-92.
[54] Rawls J., Il diritto dei popoli, Torino 2001, p. 86.
[55] Tedesco F., Diritti umani e relativismo, Roma - Bari 2009, p. 14.
[56] Baccelli L., I diritti dei popoli Universalismo e differenze culturali, Roma - Bari 2009.
[57] Santos B. de S. Diritto ed emancipazione sociale, Troina 2008, pp. 145 and 217.
[58] Rawls J. Giustizia come equità, una riformulazione, Milano 2001, p. 37.
[59] Catania A. Metamorfosi del diritto, Roma - Bari 2008, pp.17, 95-125.
[60] M. G. Cattaneo, to be published in Rivista Internazionale di Filosofia del Diritto.